



# ANTISENSE THERAPEUTICS

20 August 2003

The Companies Section  
The Australian Stock Exchange Limited  
530 Collins Street  
MELBOURNE VIC 3000

Dear Sir/Madam

**Re: Share Placement**

The Directors of Antisense Therapeutics Limited (ASX: ANP) advise that the company has completed a placement of shares to Australian institutions and sophisticated investors, raising \$5 million by the issue of 38.5 million shares at \$0.13 per share. The placement, which was managed by ABN Amro Morgans Limited, was well supported by existing shareholders as well as a number of new institutional investors and closed oversubscribed.

As part of the placement, existing shareholder, Circadian Technologies Limited, has agreed to subscribe for approximately \$1 million at \$0.13 per share. This is subject to shareholder approval which will be sought at the company's Annual General Meeting.

The funds raised through the placement will be applied to Antisense Therapeutics' drug development projects: ATL1102 for multiple sclerosis, ATL1101 for psoriasis and other drug discovery activities.

The Directors of the company will shortly provide an opportunity through a Share Purchase Plan (SPP) for all eligible shareholders of Antisense Therapeutics to buy additional shares in the company at the same price paid by sophisticated investors in this placement.

Yours sincerely

Natalie Korchev  
Company Secretary

### ***About Antisense Therapeutics Limited***

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. ANP's mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. Its two most advanced projects target Multiple Sclerosis (ATL1102), and Psoriasis (ATL1101).

ANP plans to commercialise its pipeline via licensing/collaboration agreements with major biotechnology and pharmaceutical companies.

ANP's major shareholders include Circadian Technologies Limited (ASX: CIR), Isis Pharmaceuticals Inc (NASDAQ: ISIS), Queensland Investment Corporation and the Murdoch Childrens Research Institute.

Further company details are available on the Antisense Therapeutics website.

***Contact Information:***

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director – Mark Diamond +61 3 9827 8999

Company Secretary – Natalie Korchev +61 3 9827 8999